Market capitalization | $278.60m |
Enterprise Value | $210.90m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 3.35 |
Revenue growth (TTM) Revenue growth | -100.00% |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-22.41m |
Free Cash Flow (TTM) Free Cash Flow | $-19.70m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
7 Analysts have issued a Benitec Biopharma Inc forecast:
7 Analysts have issued a Benitec Biopharma Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.35 -0.35 |
119%
119%
|
|
EBITDA | -22 -22 |
9%
9%
|
EBIT (Operating Income) EBIT | -22 -22 |
9%
9%
|
Net Profit | -21 -21 |
2%
2%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Benitec Biopharma, Inc. is a development-stage biotechnology company, which focuses on the advancement of novel genetic medicines. The firms proprietary platforms includes DNA-directed RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitates sustained silencing of disease-causing genes following a single administration. It is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy, and Chronic Hepatitis B. The company was founded on April 13, 2020 and is headquartered in Hayward, CA.
Head office | United States |
CEO | Jerel Banks |
Employees | 16 |
Founded | 2019 |
Website | www.benitec.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.